{"id":4080,"date":"2018-03-30T08:07:16","date_gmt":"2018-03-30T12:07:16","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=4080"},"modified":"2018-03-30T08:07:16","modified_gmt":"2018-03-30T12:07:16","slug":"new-filings-updated-terms-ending-3-30-18","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/new-filings-updated-terms-ending-3-30-18\/","title":{"rendered":"New Filings & Updated Terms (Ending 3.30.18)"},"content":{"rendered":"

IPO Boutique keeps apprised of the active pipeline. Currently there are 55 active IPOs in the pipeline as of March 30, 2018. No SPACs or Unit Offerings are included. While the numbers may look diminished, we outlined why \u201clooks may be perceiving\u201d when it comes to the IPO pipeline\u00a0in this article.<\/strong><\/a><\/p>\n

\"Screen<\/a><\/p>\n

NEW FILINGS<\/strong><\/span><\/p>\n

 <\/p>\n

Company: Pivotal Software, Inc.
\nSymbol: TBD
\nDescription: They provide a leading cloud-native platform that makes software development and IT operations a strategic advantage for their customers.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Morgan Stanley, Goldman Sachs & Co., Citigroup
\nCo-Manager(s): BofA Merrill Lynch, Barclays, Credit Suisse, RBC Capital, UBS Investment Bank, Wells Fargo Securities, KeyBanc Capital Markets, William Blair
\nFiled: 3-23-18
\nListed Cash Raise: $100m.<\/p>\n

Company: Surface Oncology, Inc.
\nSymbol: SURF
\nDescription: They are a clinical-stage immuno-oncology company focused on using our specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment, or the TME, for the development of next-generation cancer therapies.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Goldman Sachs, Cowen, Evercore ISI
\nFiled: 3-23-18
\nListed Cash Raise: $75m<\/p>\n

Company: Mereo Biopharma Group plc
\nSymbol: MREO
\nDescription: They are a multi-asset biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases. This is an IPO of the company’s ADSs. Their ordinary shares trade on AIM, a market of the London Stock Exchange, under the symbol MPH.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Cowen, BMO, RBC Capital
\nCo-Manager(s): JMP Securities, Cantor Fitzgerald (Europe)
\nFiled: 3-23-18
\nListed Cash Raise: $80.5m<\/p>\n

Company: FirstCaribbean International Bank Limited
\nSymbol: FCI
\nDescription: They are a leading financial institution operating throughout the English and Dutch-speaking Caribbean with a strong balance sheet and regionally-leading digital banking capabilities.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Barclays, UBS Investment Bank, CIBC Capital Markets
\nCo-Manager(s): Keefe Bruyette & Woods, Raymond James, Sandler O’Neill + Partners, Wells Fargo Securities
\nFiled: 3-23-18
\nListed Cash Raise: $100m<\/p>\n

Company: Bioceres S.A.
\nSymbol: BIOX
\nDescription: They are a fully-integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants and fertilizers.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Jefferies, Piper Jaffray, Santander
\nCo-Manager: Mirabaud Securities
\nFiled 3-23-18
\nListed: Cash Raise: $100m
\nNote: Previously Postponed in February<\/em><\/p>\n

Company: Ceridian HCM Holding Inc.
\nSymbol: TBD
\nDescription: Ceridian is a global human capital management software company.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Goldman Sachs & Co, J.P. Morgan, Credit Suisse, Deutsche Bank Securities, Barclays, Citigroup, Jefferies, CIBC Capital Markets, Wells Fargo Securities
\nCo-Manager: Baird, Canaccord Genuity, Piper Jaffray, William Blair, MUFG
\nFiled 3-26-18
\nListed: Cash Raise: $200m<\/p>\n

Company: Smartsheet Inc.
\nSymbol: TBD
\nDescription: They are a leading cloud-based platform for work execution, enabling teams and organizations to plan, capture, manage, automate, and report on work at scale, resulting in more efficient processes and better business outcomes.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Morgan Stanley, J.P. Morgan, Jefferies, RBC Capital
\nCo-Manager: Canaccord Genuity, William Blair, SunTrust Robinson Humphrey
\nFiled 3-26-18
\nListed: Cash Raise: $100m<\/p>\n

Company: ASLAN Pharmaceuticals Limited
\nSymbol: ASLN
\nDescription: They are a clinical-stage oncology-focused biopharmaceutical company based in Singapore developing novel therapeutics for global markets. We target diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Leerink Partners, Piper Jaffray
\nCo-Manager: BTIG, H.C. Wainwright & Co., CLSA
\nFiled 3-26-18
\nListed: Cash Raise: $86.25m<\/p>\n

Company: CLPS Incorporation
\nSymbol: CLPS
\nDescription: They are are a global information technology, consulting and solutions service provider focused on delivering services to global institutions in banking, insurance and financial sectors, both in China and globally.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Benchmark, Cuttone & Co.
\nFiled 3-27-18
\nListed: Cash Raise: $14.375m<\/p>\n

Company: DocuSign, Inc.
\nSymbol: DOCU
\nDescription: DocuSign accelerates the process of doing business for companies, and simplifies life for their customers and employees.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Morgan Stanley, J.P. Morgan, Citigroup, BofA Merrill Lynch, Deutsche Bank Securities
\nCo-Manager(s): JMP Securities, Piper Jaffray, William Blair
\nFiled 3-27-18
\nListed: Cash Raise: $100m<\/p>\n","protected":false},"excerpt":{"rendered":"

IPO Boutique keeps apprised of the active pipeline. Currently there are 55 active IPOs in the pipeline as of March 30, 2018. No SPACs or Unit Offerings are included. While the numbers may look diminished, we outlined why \u201clooks may be perceiving\u201d when it comes to the IPO pipeline\u00a0in this article. NEW FILINGS   Company:[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[],"class_list":["post-4080","post","type-post","status-publish","format-standard","hentry","category-ipo"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=4080"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4080\/revisions"}],"predecessor-version":[{"id":4082,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4080\/revisions\/4082"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=4080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=4080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=4080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}